Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Charles David Pauza Insider Profile
4 Followers
Charles David Pauza, Chief Science Officer Virology at Traws Pharma, holds 97.50K shares in Traws Pharma (Ticker: TRAW).
Charles David Pauza has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Charles David Pauza's holdings
Insider Roles
Chief Science Officer Virology
Roles that Charles David Pauza holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Charles David Pauza
Charles David Pauza's Trading History
List of latest transactions for each holding click on a transaction to see Charles David Pauza's performance on stock
You May Also Like
Charles David Pauza insider profile FAQ
What is the percentage of profitable transactions made by Charles David Pauza?
The percentage of profitable transactions made by Charles David Pauza is ―.
What is the average return per transaction made by Charles David Pauza?
The average return per transaction made by Charles David Pauza is ―.
What stocks does Charles David Pauza hold?
Charles David Pauza holds: TRAW stocks.
What was Charles David Pauza’s latest transaction?
Charles David Pauza latest transaction was an Uninformative Buy of ―.
What was Charles David Pauza's most profitable transaction?
Charles David Pauza’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Charles David Pauza's role in Traws Pharma?
Charles David Pauza's role in Traws Pharma is Chief Science Officer Virology.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.